Keensight acquires majority stake in Isto Biologics in $1bn deal
Private equity firm Keensight Capital has agreed to acquire a majority stake in Isto Biologics, a US-based orthobiologics specialist, from Thompson Street Capital Partners in a deal valued at around $1bn according to a report by Bloomberg.


